SUBJECT INDEX: VOLUME 45 (2005)

In the subject index, the page number refers to the first page of the communication in which the subject is addressed rather than to the specific page on which the referenced key words can be found. An "L" in parentheses following the page number indicates that the subject entry appeared in a letter to the editor; an "E" in parentheses indicates that the subject was discussed in an editorial; a "/" between numbers indicates on what page the correction for the subject entry appears.

In Volume 45 (2005), Number One (January) contains pages 1-126; Number 2 (February), pages 127-286; Number 3 (March), pages 287-458; Number 4 (April), pages 459-650; Number 5 (May), pages 651-824; Number 6 (June), pages 825-1046; Number 7 (July), pages 1047-1240; Number 8 (August), pages 1241-1402; Number 9 (September), pages 1403-1546; Number 10 (October), pages 1547-1694; Number 11 (November), pages 1695-1830; and Number 12 (December), pages 1831-2008.

A

AABB Research Foundation grants 2S:60
AB/D antigens, masking by pegylation 374
Abdominal attacks, in hereditary angioedema 1774
ABO blood group
- *ABO*O* alleles 359, 1331
- anti-A/B quantification 56
- *cis*-AB allele 50
- delayed PLT engraftment 885
- discrepancy, by usurpation of identity ..... 454(L)
- genotyping discrepancy 70
- influence of differences in PBPCT 1382
- novel alleles ..... 50, 645(L)
- *O* alleles 70
- phenotypes 359, 960
- reverse typing problems 1331
- secretor locus 1934
- tetragametic chimerism 698

ABO gene mutation 50, 1178
ABO glycosyltransferase 1663
ABO mismatch
- allogeneic HPCT ..... 643(L), 779, 960, 1676
- patient identification error 1

ABO transferase, N-terminal domain 1663
Absorption-elution techniques 1574
Additive solutions, platelet 743, 927, 1349
Adhesion of hematopoietic graft 622
Administration
- policies for new cellular therapies 4S:144
- transfusion medicine plan 4S:224

ADO 596
Adsorptions, autologous with PEG 694
Adverse events
- anti-CD36 isoantibody 803
- from blood donation, estimating probability of 1715
- photochemically-treated PLTs 1864
- transfusion-associated pulmonary sequelae ..... 1048(E)

Advia 120 5
African Americans
- D antigen ..... 1547(E)
- donor reactions ..... 1398(L)

Age of donor
- probability of reaction and 1715
- WPM formation in RBC components 1127

Agglutination, in blood group typing ..... 652(E)
Agonists 596
Albumin
- for fluid resuscitation *vs.* saline 1523
- polymerized 1221

ALL, chemotherapy-induced apoptosis 1403
Alleles
- *ABO*O* 359, 1331
- *cis*-AB 50
- HLA-DRB1 956
- A^m 63
- novel ABO ..... 50, 645(L)
- *O* 70
- *RHD* blood group 527
- variety 1183

Alloantibodies 16, 694, 1930
Alloantigens
- HPA SNP typing 654
- low-frequency 353, 1487

Allogeneic blood transfusion. *See* Blood transfusion, allogeneic
Allogeneic platelet gels, frozen-and-thawed ..... 1544(L)
Alloimmune refractoriness, prevention 1523
Alloimmune thrombocytopenic syndromes 366
Alloimmunization
- anti-D 1554, 1561
- anti-Ku 1791
- fetomaternal 550, 1487, 1791, 1799
- Max^a 1487
- PLT 761

AMD3100 295
American Red Cross 1593, 1845
Amicus blood cell separators 773
Amicus Crecendo plateletpheresis device 1373
AML 1735
Amotosalen
- FFP treatment 1362
- HTLV-I and HTLV-II inactivation 1151
- *Leischmania* inactivation 1459
- neoantigenicity, absence of 1610
- photodegradation measurement 1464
- PLT concentrate treatment 580, 1443, 1864

Amt/MEP family 2S:109
Amyloidosis, PBPC mobilization and collection 1729
Anemia
- chemotherapy-induced 1735
- chronic disease 1930
- from fetomaternal hemorrhage 539
- hemolytic 1930
- predonation screening 1585

Angioedema, C1 inhibitor concentrate for 1774
Animal models 2S:44, 2S:51, 2S:109, 1899
Annexin binding 1890
Antenatal screening 1945
Anti-A/B, rapid quantification of 56
Anti-B19 detection 1003
Antibiotic therapy 874
Antibodies. *See also specific antibodies*
- historical aspects of 1531
- neutrophil-reactive 704
- PLT-reactive 704
- RBC-reactive 704
- screening ..... 288(E)
- S-303 RBC 1739

Anti-CD36 803
Anticoagulants 1531
Anti-Cr^a 1327
Anti-D ..... 1547(E)
- affinity 975
- alloimmunization 1554, 1561
- immune response 2S:100
- immunization 520

Anti-Di^b 16
Anti-D immunization ..... 453(L), 1581
Anti-Fy^a 539
Antigens. *See also specific antigens*
- high-prevalence 1940
- historical aspects 1531
- JAHK 1315

Anti-HCV 1973
Anti-hemoglobin F 539
Anti-HNA-1c, neonatal alloimmune neutropenia 1308
Anti-HPA-1a 1165, 1945
Anti-HPA-9bw 1799

Anti-Jk^a, naturally occurring ..... 1043(L)
Anti-Jk^b 539
Anti-Ku 545, 1791
Anti-s 539
Antithrombin III, in twice-frozen plasma ..... 281(L)
Anti-Wr^a 1325
Apoptosis, chemotherapy-induced 1403
Arab blood donors 1973
Arachidonic acid 596
Arteriovenous fistula, following needle puncture for blood donation 270
Arthroplasty, postoperative infection 103
AS.TEC204 788
ATP 920
ATP-to-ADP ratio 82
Autoadsorptions, polyethylene glycol 694
Autoimmune disease
  liver 2S:51
  mixed-type hemolytic 1695
  phage display studies 2S:100
Autologous chimerism 70
Automated systems
  buffy coat-derived pooled concentrates ..... 642-643(L), 642(L)
  cell processing devices 1391
  culture system 731
  for donor history interviewing 171
  platelet concentrate preparation 743
  PLT culture bottles 1512
  quality of plasma collections 427

B

Babesia microti, in blood donors 1804
BacT/ALERT culture system
  plastic culture bottles 1267, 1512
  for PLTs 514, 1241, 1275
  vs. PCR assay 731
  vs. Scansystem method 265
BACTEC 9240 blood culture system 1138
Bacteremia 1064
Bacteria detection, in platelet concentrates 731
Bacterial contamination
  cord blood 832
  of pooled PLT concentrates 514
  Staphylococcus epidermidis 927
Bacterial detection
  culture-based systems .... 984. *See also* BacT/ALERT culture system
  enhanced PLT 984
  extended platelet storage 1832
  pH meter screening 1133
  PLTs 514, 1374, 1845
  prestorage pooled PLTs 904
  in PRP PLTs 1275
  Scansystem method 265
Bacterial virulence factor 274
BANG polymer gels 1658
B-cell superantigen 274
B19 DNA 1811
BeadChip analysis 680
Bellovac-ABT autologous blood transfusion system 202
B-glycosyltransferase enzyme 1178
Bicarbonate, bacterial inhibition 1768
Bioterror agents, donor screening for ..... 290(E), 399
Birth weight 856
Bleeding
  hemophilia clinical trial endpoints 1S:2
  massive, cardiac surgery mortality and ..... 1235(L)
  prediction during invasive diagnostic procedures 1413
  prevention, off-label rFVIIa use 1435
  rF-VIIa therapy in cardiac surgery 26
Blood banks
  blood transfusion safety 4S:159
  ISBT 128 labeling standard ..... 1054(E), 1111
  on-call physician's experiences 35
  visual inspection of blood units 459
  West Nile virus epidemic of 2003 experience 469
Blood cell preparations/products. *See also specific blood cell preparations/products*
  parvovirus B19 contamination 1811
  WBC destruction in 228
Blood cell separators, quality control indicator 773
Blood collection, in United States 141
Blood culture systems ..... 1138, 1201. *See also* BacT/ALERT culture system
Blood donation
  allogeneic, postoperative infection and 103
  autologous 103, 737
  Canadian student 149
  crisis in ..... 128(E)
  determinants of intent 945
  serial, for intrauterine transfusions 1791
  transcription-mediated assay 1988
  whole-blood 1957
Blood donation screening. *See* Predonation screening
Blood donation site, predicting donor arrival 162
Blood donors. *See* Donors
Blood group typing
  agglutination in ..... 652(E)
  DNA microarray 667
  microarray 680
  mixed-field agglutination reaction 698
  problems, nondeletional ABO*O alleles and 1331
Blood irradiator dosimetry 1658
Blood outgrowth endothelial cells 1201
Blood services network 4S:206
Blood shortages, alleviating 1118
Blood storage. *See* Storage
Blood substitutes. *See specific blood substitutes*
Blood suppliers 4S:206
Blood supply chain 4S:224
Blood transfusion, allogeneic
  JK^a immunization 956
  RBC trigger, in critically ill patients 1523
  safety 4S:159
  in United States 141
  universal leukoreduction 1632
  WBC transfer during 2S:44
Blood transfusion, autologous ..... 202, 820(L), 821(L)
Blood units, visual inspection of 459
Blood utilization review 4S:159S
Blood volume, preoperative estimation 562
Bluetongue virus inactivation 580
BNP 1056
Body weight, probability of donor reaction and 1715
Bone marrow HPC harvest, bacterial contamination 874
Bone marrow transplantation, autologous 394
Book reviews
  Immune Hemolytic anemias 640
  Textbook of Hemophilia 1981
  Transfusion Therapy: Clinical Principles and Practice (Mintz) 1689
B phenotype, weak 1178
Brazilian blood donors, first-time 1709
Bronchoscopy 1413
Buffy coat-pooled platelets
  automated systems ..... 642-643(L), 743
  preparation 634
BVDV, viral inactivation 580

C

Canada
  PLT preparation 634
  student blood donation 149
  WNV in blood donors 487
Cardiac surgery patients
  leukoreduced RBCs for 1523
  mortality, massive blood loss and ..... 1235(L)

recombinant factor VIIa in 26
S-303 RBCs for 1739
Cardiogenic shock 1481
Catalase 622
Caucasian blood donor population, D antigen ..... 1547(E)
CB unit, volume reduction 867
CD47 1496
CD34+ cells 248, 885, 1192
collection after imatinib mesylate in CML 1214
in cord blood ..... 613, 856, 1828(L)
count, cord blood unit quality and ..... 189, 455-456(L)
low yield 11
mobilization and collection 295
prefreezing *vs.* thawed content ..... 116-117(L), 117-118(L)
CD109 expression 366
CD36 isoantibody 803
CD34 protein 2S:67
CD4+ T cells 2S:51, 2S:88
Cell destruction marker 228
Cell lines, allele-specific 353
Cell separators, quality control indicator 773
Cellular therapies ..... 4S:241. *See also specific cellular therapies*
administrative policies 4S:144
safety 4S:159
Central vein cannulation 1413
Centrifugation leukapheresis 1876
CFUs 248, 984
Chemotherapy-induced anemia 1735
Chemotherapy-induced apoptosis 1403
Children
rHuEPO facilitation of autologous blood donation ..... 820(L), 821(L)
WBC-reduced split apheresis PLT concentrates 223
Chimerism, tetragametic 698
Chinese blood donors ..... 645(L), 725, 1816
Cholesterol, WPM formation in RBC components 1127
Chronic disease, anemia 1930
CIDP, idiopathic 1640
C1 inhibitor concentrate 1774
Circulatory overload 1056
Clinical trial endpoints
fluid resuscitation for traumatic injuries 1S:4
hemophilia 1S:2
transfusion requirements 1S:9
Clinical trials, regulatory perspectives 1S:14
Closed-systems
BOEC blood culture 1201
RBC glycerolization 1621
Clostridial bacteremia, secondary hemolysis 127
Clotting factors. *See* Coagulation factors
CLX containers 1356
CML 16, 1214
CMV 228, 580, 1722
Coagulation factors .... 1453, 1829(L). *See also specific coagulation factors*
congenital deficiencies 1362
in cryosupernatant 1453
storage effects 1342
Coagulation test, abnormal without procedural bleeding 1413
COBAS AmpliScreen HBV test 1247
COBE Spectra LRS 788
COBLT Study 842, 856, 1027
Colony-forming cells, content in cord blood 613
Communication, e-mail donor recruitment program 1957
Compatibility testing, pretransfusion 2S:100
Complement receptor 1 234
Complement system, therapeutics 2S:122
COM.TEC 788
Cord blood
CD34+ cell content, newborn sex and ..... 1828(L)
CMV PCR testing 1722
collection 189
cryopreservation 622
donor recruitment 842
donors, CMV testing 1722
filter 433
hematopoietic progenitor cell content 613
postthaw/postwash 1909
processing 842, 1909
SCID-repopulating activity 1899
screening 842
stem cell quality ..... 826(E), 832
storage 867
Cord blood banks 867
quality control 826, 832
standard operating procedures 842
Cord blood transplantation
allogenic adult ..... 829(E), 1027
quality, variables in ..... 189, 826(E)
Cord blood units
quality 189
selection for storage ..... 455-456(L)
Corrected count increment, posttransfusion 896
Corticoid stimulation, of PMN donors ..... 1697(E), 1701
Cost allocation method, for hospital-based clinical laboratories 1664
Cost-effectiveness analysis
anti-HPA-1a antenatal screening 1945
microbial surveillance 874
PF4 ELISA 717
Cost estimates, HCV transfusion lookback program 1020
Council on Research and Development (CORD) 2S:25
Creutzfeldt-Jakob disease 504, 1839
CR1 inhibitors 234
Critically ill patients
allogeneic RBC transfusion trigger 1523
erythropoietin for 1523
fluid resuscitation 1523
Cromer antigens 1327
CR1 structure-function 234
Cryopreservation
automated washing technique 737
CD34+ cell viability evaluation 1208
closed-system blood culture of BOECs 1201
cord blood 622
hematopoietic progenitor cells 1917
platelet quality 596
RBC recovery ..... 822(L), 823(L)
standard procedures 842
CS-3000 Plus blood cell separator 773
CXCR4 antagonist 295
CytoMate 737

D

D– 345, 520, 527
D antigens
DEL 1561
weak ..... 1547(E), 1554, 1568, 1574
DAT 704, 1327
Data envelope analysis 1118
dCE haplotype 1315
DCLHb 1S:4
DDAVP 420
Decay-accelerating factor 1327
DEHP exposure 798
DEL ..... 520, 1547(E), 1561
Delayed hemolytic transfusion reaction, massive hemolysis with pancreatitis ..... 1691(L)
Delayed hemolytic transfusion reactions 1925
DELFIA analysis 504
Delivery method, cord blood characterization 856
D_{el} phenoype 1581
Dendritic cells 181, 1899
Dermatobia hominis 1831
Dexamethasone, with lenograstim 604
DHBV, viral inactivation 580
DHPLC 1934

Diabetes 1899
Diagnostic test systems, adaptations 1097
Dipyridamole 752
DMSO 737, 1391, 1890
DNA analysis, high-throughput 681
DNA-based assays. *See* Nucleic acid testing
DNA microarray hybridization 667
DNA sequencing 527
Documentation, cord blood 832
Dodecapeptide 1221
2-DOG 1750
Dombrock blood group system 2S:92
Donation intentions, of nondonors 945
Donor history interview, automated system for 171
Donor-recipient MHC disparity 301
Donor-recipient repository ..... 1051(E), 1073
Donor recruitment 788
  cord blood 842
  e-mail 1957
  mononuclear cell 445
Donors. *See also* Predonation screening
  adverse reactions ..... 1398(L)
  Arab 1973
  Babesia microti in 1804
  deferral 1593
  first-time 1709
  G-CSF stimulated 1876
  with indeterminate HIV status, allogeneic HPCT ..... 819(L)
  infection detection rates 254
  lack of correlation of HBV DNA with HBsAg ..... 1039(L)
  leukapheresis, IV magnesium supplementation 934
  myiasis in 1831
  predicting arrival of 162
  rapid identification of iron deficiency in 5
  reactions 270
  regular, compensating for iron loss in ..... 1236(L)
  risk profiles 404
  student 945
  Toxoplasma gondii antibodies ..... 281-282(L)
  variables, cord blood unit quality and 189
DOSE-MAP film dosimetry system 1658
Dose-response relationship, lenograstim plus dexamethasone 604
D phenotype, weak, detection of 689
D+ population, *RHD* alleles 1183
Dry-heat process ..... 1011, 1692(L)

E

ECMO 651
Education, transfusion medicine profession 4S:172S
EIA
  HCV 1816, 1965
  WNV 480
ELISA 554, 1496, 1610
  anti-D affinity 975
  PF4 717
E-mail donor communication program 1957
Embryonic stem cell detection 709
Endoscopic procedures 807
Endothelial cells
  activation, in TRALI pathogenesis 2S:109
  blood outgrowth 1201
  progenitor, source of 21
Endotoxemia 1785
Engraftment
  G-CSF-mobilized PBPCs 1192
  PLT 885, 1064
Epitope mapping 1561
Epstein-Barr virus 591
Eptifibatide 420
Erythrocyte membrane-associated protein (ERMAP) 245
Erythroid engraftment 779
Erythropoiesis 969, 1229
Erythropoietic protoporphyria 208
Erythropoietin
  for critically ill patients 1523
  rHuEPO facilitation of autologous blood donation ..... 820(L), 821(L)
Ethical dilemmas ..... 1697(E)
Ethnicity
  cord blood 856
  D antigen ..... 1547(E)
  DEL types 1561
  HPA-15 alleles 366
  para-Bombay phenotype 725
  RHD alleles 1554
  Rh locus variability 293
  whole-blood donors reactions ..... 1398(L)
European multicenter study 527
European populations 1183, 1325
EVA plastic bags ..... 822(L), 823(L)

F

Fatigue, donor 1715
FcγR-mediated phagocytosis 384
Febrile nonhemolytic transfusion reactions, pathogenesis 1523
Feline conjunctivitis virus 580
Femoral angiography 1413
Ferritin, compensating for iron loss in regular donors ..... 1236(L)
Fetal and neonatal alloimmune thrombocytopenia
  low-frequency HPAs and 353, 366, 1799
  research 2S:64
  unexpected Glanzmann thrombasthenia carriers 550
Fetal DNA, cell-free 1473
Fetal hemoglobin, signaled expression 1229
Fetal RBC survival ..... 1985(L)
FFP 803, 1453
  for minimally elevated INRs ..... 1234(L)
  PCT-treated, for congenital coagulation factor deficiencies 1362
  production quality 1342
  protein C, protein S and antithrombin III in ..... 281(L)
  storage ..... 1829(L)
  TRALI risk reduction 1628
Fg 911
Fibrinogen 1011
Fibrinogen γ-chain dodecapeptide 1121
Fibrin sealants 1S:14
Fibronectin 911
Filtration, WBC. *See* Leukoreduction
Flow cytometry 504, 539, 1496
  of CD34+ cell viability 1208
  CD109 PLT surface expression 366
  HLA alloimmunization detection in PLT transfusion ..... 1399(L)
  mitochondrial function in PLTs 82
  Rh_{null} syndrome 1797
  WBC destruction in blood products 228
Fluid resuscitation 1S:4, 1523
Fluorescence 82
Freeze-drying process, fibrinogen 1011
Freeze-thaw-wash process 1391, 1890, 1909
Freeze-thaw-wash recovery ..... 822(L), 823(L)
Freezing medium, cord blood cryopreservation 622
Frequency of Agents Communicable by Transmission Study (FACTS) 500
Frozen plasma, West Nile virus detection in 480
FUT2 1934
FUT1 allele 725
FV 427
FVa 911
FVIII concentrate 427, 1003
FXI 427

G

Gamma irradiation 2S:44
G-CSF 11, 295, 1876
  with dexamethasone 604

engraftment 1192
for PMN collection ..... 1697(E)
Gene array 654
Gene knockdown 111
Genotyping 550, 1473
D 1568
HAV 1097
high-throughput RBC and PLT antigen 660
Geographic distribution of donors, weak D 1568
Germany 1097
Glanzmann thrombasthenia carriers 550
Globin-chain switching 1229
Glucocorticoid stimulation, of neutrophil donors ..... 1697(E)
Glucose consumption, PLT storage and 1349, 1504, 1750
Glycerolization, closed-system 1621
Glycolysis reduction, PLT storage 1750
Glycophingolipid 709
Glycoproteins 911
Glycosyltransferases 70, 960
GPIb 1890
Granulocyte donors, posterior subcapsular cataract risk ..... 1697(E), 1701
Granulocyte storage 1876
Granulocyte transfusion 604
Growth factor release, by plateletpheresis 414
Guillain-Barre syndrome 1640
GVHD 2S:44, 1027, 1064
ABO mismatch 779, 960
HPA mismatch 195

H

Haemonetics APc 215 1621
HAV
donor screening ..... 1037(L)
genotype 1097
magnetic-bead RNA extraction 1106
PCR assays 1097
travel-related ..... 1037(L)
Hb
donor screening ..... 1552(E)
F 1229
noninvasive screening 1585
polymerized bovine 1735
rapid identification in reticulocytes 5
HBOC-201 infusion, for Jehovah's Witness 1735
Hb Presbyterian 1785
HBsAg, lack of correlation with HBV DNA in donors ..... 1039(L)
HBV 1973
DNA in donors, lack of correlation with HBsAg ..... 1039(L)
donor deferral 1593
NAT 1106, 1247, 1988
pooled DNA testing ..... 1242(E)
prevalence *vs.* incidence 1089
Procleix ultrio assay 1258
risk, transfusion history and 807
transfusion-transmitted, in Italy 1670
viral inactivation 580
HCV
comparison of detection methods 1853
detection 1518, 1965
donor deferral 1593
early infection dynamics 994
NAT ..... 1040(L)
prevalence *vs.* incidence 1089
Procleix ultrio assay 1258
risk, transfusion history and 807
transcription-mediated assay 1988
transfusion lookback program 1020
transfusion-transmitted risk 254, 1670
viral inactivation 580
HCV EIA, signal-to-cutoff ratios 1816
Health economics 4S:224
Helper T-cell response, alloreactive 1165
Hematocrit, large-vessel 562
Hematologic malignancies, exposure to parvovirus B19 1811
Hematopoietic reconstitution 1917
Hematopoietic stem cells 1899
Hemolysis
CD34+ cell viability after cryopreservation 1208
gross 825
hyperhemolysis syndrome 1930
massive, with pancreatitis ..... 1691(L)
during PMT 1291
reduction in stored RBC concentrate 90
secondary to clostridial bacteremia 127
Hemolytic anemia 1930
Hemolytic disease of newborn 975, 1791
Hemolytic transfusion reactions
acute 1925
anti-Jk^a 956
mimicking 1291
Hemophilia, clinical trial endpoints 1S:2
Hemorrhage, fetomaternal 539
Hemostasis 1453
clinical trial regulations 1S:14
effective therapies 1404
hemophilia clinical trial endpoints 1S:2
Hemostasis-enhancing agents 1S:2
Hepatocellular carcinoma, SEN-V 1084
Hereditary angioedema, C1 inhibitor concentrate for 1774
HES sedimentation 867
HHV-8 ..... 463(E), 500
Hip replacement surgery, preoperative autologous donation 1523
History, of transfusion medicine 1531
HIV
comparison of detection methods 1853
donor deferral 1593
indeterminate status of donor, allogeneic HPCT ..... 819(L)
prevalence, incidence, residual risk in first-time blood donors 1709
prevalence *vs.* incidence 1089
transfusion-transmitted, in Italy 1670
HIV-1
latency 2S:88
Procleix ultrio assay 1258
transcription-mediated assay 1988
transfusion-transmitted risk 254
viral inactivation 580
HLA-1a, quantification 1319
HLA alloimmunization, detection by flow cytometry ..... 1399(L)
HLA antibodies 761, 1925
HLA antigens 761, 1165
HLA-DRB1 alleles 956
HLA match, PBPC transplantation and 195
HLA typing, cord blood 842
Hospital
clinical laboratories, cost allocation method 1664
transfusion, cellular processes and 4S:159S
HPA 654
HPA-1 550
HPA-3 550
HPA-15 alloantibodies 366
HPA-9b (Max^a) 1487
HPA microarray 667
HPA typing 654
HPC-A 1917
HPCs 1899, 1917
bacterial contamination 874
cord blood 613, 622, 856
thawed, DMSO in 1391
HPCT, allogeneic 295
ABO mismatch ..... 643(L), 779
donor with indeterminate HIV status ..... 819(L)
recipients, trigger for prophylactic PLT transfusion 1064
HPCT, autologous 395, 885
HPLC assay 1464

H12-polyALB 1221
HTLV 580, 1151, 1593
Human adenovirus-5, viral inactivation 580
Human platelet antigens. *See* HPA
Hybridoma, Dombrock blood group 2S:92
Hyperhemolysis syndrome 1930
Hyperimmune globulins 1160

I

IgG antibodies 56
IgG fragments, in liquid IVIG 1601
IgM, cytotoxic activity against PMNs ..... 115-116(L)
IL-2 expression 960
Imatinib mesylate 1214
Immigrants, parentage analysis 440
Immune cytopenias 384
Immune pancytopenia, oxaliplatin-induced 704
Immune responses 2S:44
Immune thrombocytopenia 287
Immune tolerance, inducing across MHC barrier 181
Immunoblotting, Dombrock glycoprotein 2S:92
Immunofluorescence assay 554
Immunomodulation, transfusion-related 2S:51
Incidence, transfusion-transmissible viral infections 1089
Inclusion body myositis 1640
Indirect hemagglutination test 554
Infection. *See also* Transfusion-transmitted infections
  line-related 1632
  postoperative 103
Infectious agents, donor-recipient repository ..... 1051(E), 1073
Information technology 4S:189
INRs ..... 1234(L), 1413, 1435
Integrins 1165, 1192
INTERCEPT Blood System 1443, 1464, 1610
Interferon therapy, SEN-V 1084
Intraoperative blood loss, living-donor liver transplantation 879
Intrauterine transfusions 1791
Invasive diagnostic procedures, predicting bleeding during 1413
Iron binding 927, 1768
Iron deficiency, rapid identification in blood donors 5
Iron loss, compensating for in regular donors ..... 1236(L)
ISBT 128 Code ..... 1054(E), 1111
Isoagglutinins 1331, 1676
Isoantibody 803
isohemagglutinins 779
Isosulfan blue dye 1047
Italy, transfusion-transmitted infections in 1670
IVIG 1601, 1640

J

JAHK (RH53) antigen 1315
Japanese woman, secondary anti-D immunization 1581
JC-1 assay 920
JK^a immunization 956
Joint arthroplasty, postoperative blood drainage quality 202

K

Kell blood group system 545, 969, 1382
Kidney biopsy 1413
Knockout murine transfusion model 301
Knops system antigens, CR1-associated 2S:122
Ko (Knull) phenotype 1791
Korean persons, D– 345
K^0 phenotype, in Swedish population 545
Kuwait 1973

L

Labeling
  cord blood 832
  informatics and 4S:189
  ISBT 128 standard ..... 1054(E), 1111
Lactate production, PLT storage 1349, 1504, 1750
Lanthanide fluoroimmunoassay, enhanced 504
Large-volume leukapheresis 248, 934
Leishmania inactivation 1459
Lenograstim. *See* G-CSF
Leukapheresis 248, 445
Leukodepletion 1836
Leukoreduction
  Epstein-Barr virus removal 591
  filters 21, 1839
  hemolysis reduction in stored RBC concentrate 90
  landmark studies 1523
  prestorage pooled PLTs 904
  universal 1632
Light Cycler RT-PCR infectivity assay 1011, 1097
Lineage depletion 315
Line-related infections 1632
Liver biopsy 1413
Liver disease, SEN-V 1084
Liver transplantation, living donor 879
Living-donor liver transplantation 879
Luke antigen 709
Lymphocyte subset content, cord blood 856

M

MagNA Pure-COBAS AmpliScreen method 1518
Magnesium, during leukapheresis 934
Magnetic bead technology 1106
MAIGA assay 1308
MAIPA assay ..... 288(E), 704, 1319
MAIRA assay 1496
Major histocompatibility complex 181, 301
Maleimidophenylppolyethlene glycol 374
Male-to-male sexual experience, on donor risk profile 404
Maternal antibodies, anti-HNA-1c 1308
Maternal blood, fetal RBC survival ..... 1985(L)
Maternal immunization 353
Maternal plasma, cell-free fetal DNA in 1473
Maternofetal alloimmunization 550, 1487, 1791
Mathematical algorithm, for preoperative blood volume quantification 562
Max^a (Anti-HPA-9bw) 1799
MCS+ LN9000 blood cell separator 773
MCS Plus plateletpheresis device 1373
Medical coordinating center 842
Megakaryocyte-erythroid progenitor cells 969
Metabolic suppression, for PLT storage 214
Mexican blood donors, *Toxoplasma gondii* antibodies ..... 281-282(L)
MHC antigens 2S:44
Microarray-based genotyping 654
Microbial contamination, HPC grafts 874
Microbial surveillance, cost-effectiveness 874
Microchimerism, posttransfusion 1280
Migration of hematopoietic graft 622
Minipool screening
  HBV DNA ..... 1242(E), 1247
  HCV 1853
  viral RNA and DNA extraction 1106
Minor histocompatibility antigens 960
Mirasol pathogen reduction technology 920
Mirasol PRT 911
Mixed connective tissue disease 1695
Molecular characterization, of D– individuals 345
Monoclonal antibodies 315
  anti-D 975
  B2 709
  for detection of anti-HNA-1c 1308
  rituximab ..... 643(L), 1481
Monocyte enrichment 433
Monolisa HCV Ag-Ab ULTRA 1965
Mononuclear cell counts 445
Mononuclear phagocytes 384
Mortality
  in cardiac surgery ..... 1235(L)

transfusion-related 814
transplant-related 1382
Motivation, for blood donation 149
MSGG 709
MTT assay 920
Multicenter evaluation
of off-label rFVIIa use 1435
of Procleix ultrio assay 1258
of transcription-mediated assay 1988
Multiple sclerosis 1640
Multiplex PCR 660, 667
Multi-step back flush procedure 433
Mutations
ABO gene 50, 1178
FUT1 725
A gene 63
JAHK-specific 1315
missense 1663
RHce 1797
Myasthenia gravis 1640
Myiasis, in donor 1831

N

NAT. *See* Nucleic acid testing
National Blood Foundation 2S:41
grant recipients 2S:130
research funding 2S:67, 81
Scientific Research Grants Program, history 2S:25
Needle puncture for blood donation, arteriovenous fistula after 270
Neoantigens 1610
Neonatal alloimmune neutropenia, anti-HNA-1c 1308
Neonatal alloimmune thrombocytopenia 1945
Netherlands, blood donors 945
Neuroendocrine sympathoadrenal precursors 709
Neurology, IVIG use in 1640
Neutrophil collection 604
Neutrophil donors, glucocorticoid stimulation ..... 1697(E)
Neutrophil engraftment 779
Neutrophil mobilization 604
Neutrophil priming, TRALI and 2S:109
NIH public access policy ..... 1700(E)
NK cells 1899
Non-transferrin-bound iron 927
Normovolemic hemodilution, acute 562
Nuclear cells 1917
Nucleic acid testing 1097
amplification ..... 1242(E), 1518
antenatal 1945
for bioterror agents 399
CMV 1722
HCV 994, 1518, 1965
minipool 254, 492, 1106
rapid, in resource-poor settings 133
sensitivity 1853
WNV. *See* West Nile Virus NAT
Nucleocapsid proteins 1965

O

Obituary
Kruskall, Margot 1982
Oberman, Harold Austen 283
van Loghem, J.J. 1823
Off-label rFVIIa use 1435
O phenotype 885
Optipress II method 867
OrbiSac system 743
Oriental blood donor population, D antigen ..... 1547(E)
Orthopedic surgery, postoperative infection 103
Orthopoxviruses 399
Oxaliplatin-induced immune pancytopenia 704
Oxygen, in globin-chain switching 1229
Oxygen consumption, bacterial contamination detection 984

P

Pall Bacterial Detection System 984
Pall BDS 265
Pancreatitis, with massive hemolysis ..... 1691(L)
Para-Bombay phenotype 725
Paraprotein-associated polyneuropathy 1640
Parasitemia, in donors 1804
Parasitic-borne infections 1831
Parentage, sibling pretenders 440
Parvovirus B19 ..... 580, 1106
in autologous BMT 394
contamination of blood cell preparations/products 1811
dry-heat inactivation ..... 1011, 1692(L)
transmission 1003
PAS-27a additive solution 1349
Pathogen-reduction technology 1459, 1864
controlling transfusion-associated risks 4S:224
PLT function 911
PLT mitochondrial integrity 920
PLTs 1523
prestorage pooled PLTs 904
riboflavin with UVA 1335
S-303 1739
Patient identification error 1
PBMNCs, source of 21
PBPCs
collection, low yields 11
mobilization/collection, for amyloidosis 1729
PBPCT, allogeneic 885
ABO-mismatched 960, 1382
alloantibodies after 16
HLA match and 195
IV magnesium supplementation 934
with major ABO mismatch 1676
PCR ..... 133, 680, 731, 1106. *See also* RT-PCR
anti-B19 detection 1003
CMV 1722
Dombrock blood group assay 2S:92
PCR inhibition assay, for PCT 1464
Pegylation, thiolation-mediated 376
PeliCheck reference panels 1988
Percutaneous coronary interventions, decreasing ischemic complications 420
Percutaneous mechanical thromboectomy, hemolysis during 1291
Peripheral blood HPC harvest, bacterial contamination 874
PF4 717
Phage display technology 2S:100
Phagyocytosis, FcγR-mediated 384
Phenotypes 550
A 359
ABO 960
blood group A 359
DEL 520
H-deficient 725
A^m 63
pH meter, for bacterial screening 1133
Phosphatidylserine 1496
Photochemical inactivation
efficacy, PCR inhibition assay of 1464
FFP 1362
HTLV-I and HTLV-II 1151
INTERCEPT Blood System 1610
Leishmania 1459
PLT concentrate 580, 1443, 1464
TP photosensitizer for 752
pH testing
PLT medium 596
as PLT quality indicator 773, 920
of single-donor PLTs ..... 656(L)
Physician, blood bank 35
Placental elution 1327

Plasma
- amotosalen interactions ... 1610
- amotosalen photochemical inactivation HTLV-I and HTLV-II ... 1151
- citrated ... 927
- iatrogenic green ... 1047
- from leukodepleted whole blood ... 427
- quality from automated apheresis ... 427
- solvent/detergent ... 1628

Plasma exchange ... 1481
- morphine overdose in sickle cell patient ... 825
- for TTP ... 41, 1453, 1523

Plasmapheresis, for EPP ... 208
Plasma volume ... 562
Plasmodium falciparum malaria, vaccine development ... 2S:81
Plasticity of erythropoiesis ... 1229
Plasticizer ... 798
Platelet activation ... 904, 1349, 1750
Platelet additive solutions ... 743, 927, 1349
Platelet aggregation, in vitro ... 596
Platelet alloantigen ... 353
Platelet alloimmunization ... 761
Platelet antigens ... 195, 288(E), 660
Platelet collection devices, quality control indicator for ... 773
Platelet concentrate ... 420, 1459, 1504
- bacteria contamination detection ... 265, 731, 984, 1138
- buffy coat-derived pooled, automated systems for ... 642-643(L), 642(L)
- double-unit ... 788
- hyperconcentrated *vs.* standard ... 1349
- mitochondrial function in ... 82
- non-transferrin-bound iron ... 927
- residual tissue factor in ... 572
- single-unit ... 788
- storage, transient metabolic suppression for ... 214
- virus inactivation ... 580
- volume-reduced ... 651
- WBC-reduced split apheresis for pediatric use ... 223

Platelet concentrates
- amotosalen interactions ... 1610
- amotosalen photochemical inactivation HTLV-I and HTLV-II ... 1151
- bacterial contamination detection ... 1241, 1845
- bacteriologic screening ... 514
- correlation of morphology with recovery and survival ... 2S:72
- engraftment ... 779, 885
- function, storage temperature and ... 1407
- leukoreduced, stored in CLX containers ... 1356
- pathogen inactivation ... 1523
- pathogen reduction methods ... 1335
- pH meter for bacterial screening ... 1133
- pooled buffy coat ... 634
- prestorage pooling ... 896
- quality assessment ... 596
- radiolabeled ... 2S:28
- reticulated ... 766
- viability assessment ... 1143

Platelet derivatives, tissue regeneration ... 1759
Platelet-derived growth factor ... 414
Platelet glycoprotein, helper T-cell response ... 1165
Platelet glycoprotein IIB/IIIA receptor antagonists ... 420
Platelet mitochondria ... 920
Platelet morphology ... 1750
Plateletpheresis ... 1845
- growth factor release ... 414
- processing time ... 1373
- WBC-reduced split apheresis for pediatric use ... 223
- yields ... 788

Plateletpheresis machines, randomized crossover trial ... 1373
Platelet pools ... 1512
Platelet resuspension, plasma *vs.* saline ... 596
Platelet-rich plasma ... 1275, 1512
Platelet-specific antibodies ... 761
Platelet-specific antigens ... 761, 803, 1487
Platelet storage
- bacterial detection ... 1832
- DEHP exposure ... 798
- freeze-thaw process ... 1890
- prestorage pooling ... 896
- removal of supernatant solution ... 1890

Platelet storage medium ... 634
Platelet substitutes ... 1221
Platelet target ... 788
Platelet transfusion ... 366, 766, 896
- anti-D immunization risk ... 453(L)
- DEHP exposure ... 798
- HLA alloimmunization detection by flow cytometry ... 1399(L)
- prophylactic ... 1064, 1523
- refractoriness ... 803
- risk reduction ... 911
- threshold ... 1064
- in thrombotic thrombocytopenic purpura ... 1984(L)

Platelet transfusion-associated viral disease ... 580
Platelet viability, storage temperature and ... 1407
PMN donors, posterior subcapsular cataract risk ... 1697(E), 1701
PMNs
- activity after storage ... 1876
- IgM cytotoxic activity against ... 115-116(L)

Polyethylene glycol ... 374, 694
Polymorphisms ... 698, 1934
- HPA-15 ... 366
- Rhesus box ... 338

Porcine parvovirus, dry-heat sensitivity ... 1692(L)
Porcine RBCs ... 1035(L)
Posterior subcapsular cataract, risk in PMN donors ... 1697(E), 1701
Postoperative blood loss ... 1302
Postoperative chronic wounds, frozen-and-thawed allogeneic platelet gels for ... 1544(L)
Postoperative infection, after WBC-filtered blood components ... 103
Potassium, extracellular ... 1295
PPV ... 580
Prediction method
- of bleeding during invasive diagnostic procedures ... 1413
- or blood donor arrival ... 162

Predonation screening ... 1518, 1853, 1965
- for anemia ... 1585
- for bioterror agents ... 290(E), 399
- HAV RNA ... 1037(L)
- Hb ... 1552(E)
- with rapid tests, in resource-poor settings ... 133
- in resource-restricted settings ... 130(E)
- for *T.cruzi*, sensitivity/specificity of ... 554554
- for West Nile virus ... 460(E), 487

Predonation testing, in resource-restricted settings ... 1541(L), 1542(L)
Pregnancy ... 1791
- anti-Cr^a ... 1327
- JK^a immunization ... 956

Preoperative autologous blood donation ... 103
Presbyterian Hb ... 1785
Prestorage pooling ... 896, 904
Prion protein ... 504
Prion removal ... 1836, 1839
Probability estimation, of adverse event from blood donation ... 1715
Procleix ultrio HIV-1 and HCV assay, validation ... 1258
Procleix WNV assay ... 1540(L)
Procoagulant activity ... 572
Programmed cell death. *See* Apoptosis
Propidium iodide ... 228
Prosorba column ... 274
Prostaglandin E_2 ... 433
Protective immunity, in malaria vaccine development ... 2S:81
Protein C, in twice-frozen plasma ... 281(L)
Protein S, in twice-frozen plasma ... 281(L)

Proteomic analysis, RBC supernatants 1426
Prothrombin time, prolonged 1413
P-selectin 904
Pulmonary sequestration, animal models 2S:109
Pure red cell aplasia ..... 643(L)
Purification, SARS hyperimmune globulin 1160
PUVA 2S:44, 1459
PVC plastic bags ..... 822(L), 823(L)

Q

Quality control
  pH for apheresis PLTs 773
  umbilical cord blood stem cells 826, 832
Quality markers 1504
Quantification
  HLA-1a 1319
  rapid, anti-A/B 56
  RPs after PLT transfusion 766
Quantitative assay 1496

R

Race
  molecular characterization of D–individuals 345
  probability of donor reaction and 1715
  RH locus variability 327
RADAR repository ..... 1051(E), 1073
Radiolabeling 2S:28, 2S:72, 1143
Randomized controlled trials 896
  IVIG use in neurology 1640
  landmark 1523
  SPRINT trial 1864
Rapid tests
  anti-A/B quantification 56
  for donor screening in resource-poor settings 133
  genotyping 667
  high-throughput DNA analysis 680
  for iron deficiency in donors 5
RBC agglutination, in vivo in small child 1
RBC aplasia 394
RBC components, white particulate matter formation 1127
RBC concentrate, hemolysis reduction in 90
RBC depletion 867
RBC destruction, prevention 234
RBC engraftment, delayed 394
RBC exchange transfusion, EPP and 208
RBC genotyping 660
RBC glycerolization, Closed-system 1621
RBC indexes, in blood donors 5
RBC membrane proteins 969
RBC phenotype, porcine ..... 1035(L)
RBC storage 374
RBCs 1523
  leukoreduced, for cardiac surgery 1523
  low-affinity Hb-containing for endotoxemia 1785
  percentage of hypochromatic mature, rapid identification of 5
  radiolabeled 2S:28
  survival 1925
RBC storage ..... 822(L), 823(L)
  protein accumulation, 1426
  TP photosensitizer and DP 752
RBC storage lesions 1426, 1496
RBC supernatants, proteomic analysis 1426
RBC suspensions, after irradiation and washing, extracellular K+ in 1295
RBC transfusions
  complications 814
  long-term 761
  tranexamic acid reduces requirements after TKA 1302
RCC, prion removal 1836, 1839
RealArt™ Orthopox LC PCR kit 399
Recombinant antigens 353
Recombinant factor VIIa, in cardiac surgery 26
Recovered plasma 427
Recovery of hemopoietic cells 1899
Recruitment 4S:224
Red cell antibodies, hemolytic transfusion reactions 1925
Red cell indexes, rapid identification of iron deficiency in donors 5
Red cell volume 562
Reduced-intensity conditioning regimen 195
Reference DNA 353
Regenerative stem cell therapy 315
Regional blood centers 1111
Renal carcinoma cells 709
Research 4S:241
  NBF funding 2S:67
  new cellular therapies, administrative policies for 4S:144
Resource allocation 4S:224
Resource-restricted settings
  alleviating blood shortages 1118
  predonation testing ..... 130(E), 1541(L), 1542(L)
Reticulated platelets 766
rFVIIa, off-label use 1435
RH53 antigen, molecular basis 1315
Rh blood group system
  anti-D immunization risk ..... 453(L)
  ethnic variability of locus 293
  influence of differences in PBPCT 1382
  protein functions 2S:117
RHCE gene 1315
RHce mutation 1797
RHD alleles 1183, 1554, 1568
RHD blood group, alleles 527
RHD gene 327, 338, 520, 1581
RHD genotyping 1473
RHD zygosity 327, 338
Rhesus box 345
Rhesus box polymorphism 338
RH locus variability 327
Rh_{null} syndrome 1797
Rhoptery-associated membrane antigen 2S:81
rHu-EPO
  for autologous blood donation ..... 820(L), 821(L)
  for hemolytic disease of newborn 1791
rHuG-CSF, for anti-HNA-1c neonatal alloimmune neutropenia 1308
Riboflavin, with UVA 1335, 1750
Rituximab ..... 643(L), 1481
RNA detection, WNV assay 97, 480
RNA interference 111
RT-PCR 1097, 1106, 1473
  B-19-specific infectivity assay 1011
  compared with BacT/ALERT system 731
  expression of Kell blood group proteins 969
  for orthopoxviruses 399
  RH locus variability 327

S

Saccharomyces cerevisiae expression studies 2S:109
Safety 4S:159, 1676
  blood services network 4S:206
  computer solutions to reduce errors 4S:189
  photochemically-treated PLTs 1443, 1864
  S-303 RBCs 1739
Saline, for fluid resuscitation *vs.* albumin 1523
SARS, hyperimmune globulin purification 1160
SARS-HcoV, viral inactivation 580
SCAN 1940
Scansystem method 265
SCER 1940
Scianna blood group 245, 1940
Semiautomated system, for RBC depletion 867
Sensitivity
  of BacT/ALERT culture system 1275
  of enhanced bacterial detection system 984
  HCV NAT ..... 1040(L)

noninvasive Hb screening 1585
PCR 731
pH testing of single-donor apheresis platelets ..... 656(L)
of WNV Nucleic acid testing 492
Sensitivity, of nucleic acid amplification tests 1853
SEN-V 1084
Sepsis 1632
low-affinity Hb-containing RBCs for 1785
posttransfusion 814
Septic shock, posttransfusion 814
Serologic tests 554, 704
Dombrock blood group system 2S:92
placental elute 1327
Rh_{null} syndrome 1797
Sex
of donor, white particulate matter (WPM) formation in RBC components 1127
hematopoietic progenitor cell content in cord blood 613
of newborn CD34+ cord blood content and ..... 1828(L)
probability of donor reaction and 1715
sGPV 1505
Short tandem repeat 440
Sibling pretenders, to parentage 440
Sickle cell disease ..... 825(E)
Signal-to-cutoff ratios, for HCV EIA 1816
Simian adenovirus 15, viral inactivation 580
Single-nucleotide polymorphism 654, 660, 680
Solid-phase red cell adherence system 689
Solvent/detergent plasma 1628
Spanish population, Wr^a antigen and anti-Wr^a in 1325
Specificity, noninvasive Hb screening 1585
Spinal surgery, pediatric ..... 820(L), 821(L)
Spleen, in immune thrombocytopenia 287
SPRINT trial 1864
S-303 RBCs 1739
Staphylococcal protein A immunomodulation 274
Staphylococcus epidermidis 927, 1768
STAR antigen 245
Stem cell therapy 315
Storage
cord blood 867
FFP ..... 1342, 1829(L)
liquid IVIG 1601
platelet activation during 1349
PLT 572
PLT viability assessment 1143
room temperature 1407
stress-enhanced PLT storage lesions 1750
temperature 1407
WBC-reduced split apheresis PLT concentrates 223
white particulate matter (WPM) formation in RBC components 1127
Storage containers, leukoreduced platelets 1356
Stress 1504, 1750
STR typing 698
Surface plasmon resonance method, anti-A/B quantification 56
Surgery, postoperative blood drainage quality 202
Survival, fetal RBCs ..... 1985(L)
Swedish population, K^0 phenotype in 545

T

TACO 1056
TaqMan 5′ nuclease assay 654
T-cell responses 960
Tetragametic chimerism 698
Thalassemia 761
Theory of Planned Behavior 945
Therapeutic plasma exchange. *See* Plasma exchange
Thimerosal 384
Th1 immunity 2S:51
Thiol-disulifide groups 384
Thiopyrylium photosensitizer 752
Thrombocytopenia 803, 1443
Thrombotic thrombocytopenic purpura
plasma exchange for 1453, 1523
plasma infusion for 1523
platelet transfusion ..... 1984(L)
refractory 1481
research 2S:60
vincristine with plasma exchange for 41
Thromboxane A2 597
Tissue factor 572
Tissue regeneration, PLT-induced 1759
TNC count, cord blood unit quality 189
Total knee arthroplasty 1302
Toxoplasma gondii antibodies ..... 281-282(L)
TRALI ..... 2S:109, 1042(L), 1628
Tranexamic acid 1302
Transcription-mediated amplification assay 994, 1988
Transforming growth factors 2S:51, 414
Transfusion-associated adverse pulmonary sequelae ..... 1048(E)
Transfusion-associated circulatory overload 1056
Transfusion history, HBV and HCV risk 807
Transfusion immunomodulation 2S:33
Transfusion lookback program, HCV 1020
Transfusion medicine
advancing, strategies for 4S:241
clinical trials network 1404
historical review 1531
as profession 4S:172S
Transfusion providers 4S:206
Transfusion reaction, hyperhemolysis syndrome 1930
Transfusion-related acute lung injury (TRALI) ..... 2S:109, 1042(L), 1628
Transfusions. *See also specific types of transfusions*
clinical trial regulations 1S:14
requirements, clinical endpoints 1S:9
Transfusion-transmitted infections. *See also specific infections*
cord blood testing 832
HHV-8 500
in Italy 1670
male-to-male sexual experience on donor risk profile 404
reducing by NAT 469
SEN-V 1084
transfusion history 807
viral, prevalence of 1089
Transmissibility by transfusion, donor-recipient repository ..... 1051(E), 1073
Transportation 1504
TRAP study 1523
Trauma
clinical trial regulations 1S:14
fluid resuscitation 1S:4
posttransfusion microchimerism 1280
Trehalose 622
TRICC trial 1523
Triglycerides, WPM formation in RBC components 1127
Trima Accel plateletpheresis device 1373
Trima v4 apheresis platform 788
Trypan blue exclusion staining 1208
Trypanosoma cruzi 554
T-Sol additive solution 1349

U

Umbilical cord blood. *See* Cord blood
United States
blood collection and transfusion in 141
clinical trial regulations 1S:14
HHV-8 transmission via blood transfusion 500
PLT preparation 634
West Nile virus epidemic of 2003 469
Universal leukoreduction 1632
UVA irradiation 580
amsotosalen interactions 1610
HTLV inactivation 1151
Leishmania inactivation 1459

PLT concentrate 580, 1443, 1864
with riboflavin 1335
UVB irradiation 2S:44, 181, 1523

V

Vaccine development, *plasmodium falciparum* malaria 2S:81
Vaccinia virus inactivation 580
Validation
BACTEC 9240 blood culture system 1138
efficacy standard for stored PLTs 1143
of Procleix ultrio HIV-1 and HCV assay 1258
Variable tandem repeat 440
Venous access devices, indwelling 1632
Vincristine, for thrombotic thrombocytopenic purpura 41
Viral infections. *See also specific viruses and viral infections*
markers, in Arab blood donors 1973
temporarily deferred donors 1593
transfusion-transmitted risk 254
viremia detection 1853
Viral residue risk 1089
Viruses. *See also specific viruses*
Virus inactivation 580, 752
Vitamin B2 with UVA 1335
VNTR typing 698
Volume reduction, CB unit 867
Voluntary blood donation, recruitment 4S:224

W

Waiting time, at blood donation site 162
Washing
automated 737, 1391
DEHP exposure and 798
extracellular K+ and 1295
WBC-reactive antibodies, in S/D plasma 1628
WBC reduction. *See* Leukoreduction
WBCs
destruction 228
microchimerism 1280
persistence in murine transfusion model 301
West Nile virus
detection in frozen plasma components 480
epidemic 469
prevention of transmission ..... 1540(L)
viral inactivation 580
West Nile virus NAT
assay comparison ..... 1540(L)
donor screening ..... 460(E), 487
sensitivity of 492
working reagent 97
yield 469
WPM formation, in RBC components 1127
Wr^a antigen and anti-Wr^a 1325
WWF 911

X

Xenopus oocyte expression studies 2S:109
Xenotransplantation model 1899

Y

Yeast expression studies 2S:109
Yersinia enterocolitica 815